Association of coffee consumption and non-motor symptoms in drug-naïve, early-stage Parkinson's disease

Cho, Bang‐Hoon; Choi, Seong-Min; Kim, Joon‐Tae; Kim, Byeong C.

doi:10.1016/j.parkreldis.2018.02.016

Cited by 37 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to green tea, coffee is also a popular beverage worldwide. Epidemiological studies have shown the lifespan-extending benefits of coffee-consuming habits [78] and the potential of coffee consumption in alleviating the severity of PD [79]. Chlorogenic acid largely presents in both caffeinated and decaffeinated coffee, with a potent free radical scavenging activity and antioxidant effects [80].…”

Section: Polyphenols In Neurodegenerative Diseasesmentioning

confidence: 99%

Dietary Anti-Aging Polyphenols and Potential Mechanisms

et al. 2021

View full text Add to dashboard Cite

For years, the consumption of a diet rich in fruits and vegetables has been considered healthy, increasing longevity, and decreasing morbidities. With the assistance of basic research investigating the potential mechanisms, it has become clear that the beneficial effects of plant-based foods are mainly due to the large amount of bioactive phenolic compounds contained. Indeed, substantial dietary intervention studies in humans have supported that the supplementation of polyphenols have various health-promoting effects, especially in the elderly population. In vitro examinations on the anti-aging mechanisms of polyphenols have been widely performed, using different types of natural and synthetic phenolic compounds. The aim of this review is to critically evaluate the experimental evidence demonstrating the beneficial effects of polyphenols on aging-related diseases. We highlight the potential anti-aging mechanisms of polyphenols, including antioxidant signaling, preventing cellular senescence, targeting microRNA, influencing NO bioavailability, and promoting mitochondrial function. While the trends on utilizing polyphenols in preventing aging-related disorders are getting growing attention, we suggest the exploration of the beneficial effects of the combination of multiple polyphenols or polyphenol-rich foods, as this would be more physiologically relevant to daily life.

show abstract

Section: Polyphenols In Neurodegenerative Diseasesmentioning

confidence: 99%

Dietary Anti-Aging Polyphenols and Potential Mechanisms

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Coffee has been inversely associated with PD risk [ 180 ]. A cross-sectional study involving treatment-naïve PD patients showed that coffee drinking was significantly associated with a reduced severity in the cognitive domain of the non-motor symptom assessment scale [ 181 ]. In the Parkinson’s Environment and Gene study PD patients also reported on their average caffeinated beverage consumption and ever coffee consumption was associated with less decline in MMSE [ 138 ].…”

Section: Protective Factorsmentioning

confidence: 99%

Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors

Gonzàlez‐Latapi

Bayram

Litvan

et al. 2021

Behavioral Sciences

View full text Add to dashboard Cite

Cognitive impairment is a common non-motor symptom in Parkinson’s Disease (PD) and an important source of patient disability and caregiver burden. The timing, profile and rate of cognitive decline varies widely among individuals with PD and can range from normal cognition to mild cognitive impairment (PD-MCI) and dementia (PDD). Beta-amyloid and tau brain accumulation, oxidative stress and neuroinflammation are reported risk factors for cognitive impairment. Traumatic brain injury and pesticide and tobacco exposure have also been described. Genetic risk factors including genes such as COMT, APOE, MAPT and BDNF may also play a role. Less is known about protective factors, although the Mediterranean diet and exercise may fall in this category. Nonetheless, there is conflicting evidence for most of the factors that have been studied. The use of inconsistent criteria and lack of comprehensive assessment in many studies are important methodological issues. Timing of exposure also plays a crucial role, although identification of the correct time window has been historically difficult in PD. Our understanding of the mechanism behind these factors, as well as the interactions between gene and environment as determinants of disease phenotype and the identification of modifiable risk factors will be paramount, as this will allow for potential interventions even in established PD.

show abstract

“…In this regard, it is important to note that at least six longitudinal studies support an inverse relationship between caffeine consumption and decreased memory impairments associated with aging as well as a reduced risk of developing dementia and Alzheimer's disease, including the Maastricht Aging Study (Hameleers et al, 2000;van Boxtel et al, 2003), the Canadian Study of Health and Aging (CSHA) (Lindsay et al, 2002), the FINE study (van Gelder et al, 2007), the French Three Cities study (Ritchie et al, 2007), the Cardiovascular risk factors, Aging and Dementia (CAIDE) study (Eskelinen et al, 2009), the Honolulu-Asia Aging Study (Gelber et al, 2011). Furthermore, in a cross-sectional study involving 196 early-stage, treatment-naïve PD patients, coffee drinking was significantly associated with a reduced severity of the mood/cognition domain of NMSS in patients with PD (p = 0.003) (Cho et al, 2018). These epidemiological findings raise the possibility of caffeine as therapeutic treatment for cognitive impairments in PD.…”

Section: Caffeine and Cognitive Improvement In Pdmentioning

confidence: 99%

Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms

2020

View full text Add to dashboard Cite

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by dopaminergic neurodegeneration, motor impairment and non-motor symptoms. Epidemiological and experimental investigations into potential risk factors have firmly established that dietary factor caffeine, the most-widely consumed psychoactive substance, may exerts not only neuroprotective but a motor and non-motor (cognitive) benefits in PD. These multi-benefits of caffeine in PD are supported by convergence of epidemiological and animal evidence. At least six large prospective epidemiological studies have firmly established a relationship between increased caffeine consumption and decreased risk of developing PD. In addition, animal studies have also demonstrated that caffeine confers neuroprotection against dopaminergic neurodegeneration using PD models of mitochondrial toxins (MPTP, 6-OHDA, and rotenone) and expression of α-synuclein (α-Syn). While caffeine has complex pharmacological profiles, studies with genetic knockout mice have clearly revealed that caffeine’s action is largely mediated by the brain adenosine A2A receptor (A2AR) and confer neuroprotection by modulating neuroinflammation and excitotoxicity and mitochondrial function. Interestingly, recent studies have highlighted emerging new mechanisms including caffeine modulation of α-Syn degradation with enhanced autophagy and caffeine modulation of gut microbiota and gut-brain axis in PD models. Importantly, since the first clinical trial in 2003, United States FDA has finally approved clinical use of the A2AR antagonist istradefylline for the treatment of PD with OFF-time in Sept. 2019. To realize therapeutic potential of caffeine in PD, genetic study of caffeine and risk genes in human population may identify useful pharmacogenetic markers for predicting individual responses to caffeine in PD clinical trials and thus offer a unique opportunity for “personalized medicine” in PD.

show abstract

Association of coffee consumption and non-motor symptoms in drug-naïve, early-stage Parkinson's disease

Cited by 37 publications

References 29 publications

Dietary Anti-Aging Polyphenols and Potential Mechanisms

Dietary Anti-Aging Polyphenols and Potential Mechanisms

Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors

Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms

Contact Info

Product

Resources

About